Septerna (SEPN) Current Deferred Revenue (2025 - 2026)
Septerna's quarterly Current Deferred Revenue came in at $59.8 million in Q1 2026, down 4.02% quarter-over-quarter from $62.3 million in Q4 2025.
Septerna has reported Current Deferred Revenue for 2 years, with the latest figure at $59.8 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $59.8 million; the trailing twelve-month figure through Mar 2026 stood at $59.8 million (changed N/A YoY), and the FY2025 full-year result was $62.3 million, changed N/A from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $59.8 million, down from $62.3 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $62.3 million in Q4 2025, with the low at $59.8 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.76 Mn |
| Dec 31, 2025 | 62.27 Mn |
| Sep 30, 2025 | 61.60 Mn |